The Technical Analyst
Axsome Therapeutics Inc [AXSM]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Axsome Therapeutics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
3.32% $67.90
America/New_York / 19 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 3 216.72 mill |
| EPS: | -5.27 |
| P/E: | -12.88 |
| Earnings Date: | May 05, 2024 |
| SharesOutstanding: | 47.37 mill |
| Avg Daily Volume: | 0.732 mill |
| RATING 2024-04-19 |
|---|
| B+ |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Strong Buy | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -12.88 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -2.19x |
| Company: PE -12.88 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$62.45 (-8.03%) $-5.45 |
| Date: 2024-04-19 |
| Expected Trading Range (DAY) |
|---|
|
$ 64.05 - 71.75 ( +/- 5.67%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-01 | Jacobson Mark L. | Buy | 24 662 | Common Stock |
| 2024-04-01 | Jacobson Mark L. | Sell | 24 662 | Stock Option (Right to Buy) |
| 2024-04-01 | Jacobson Mark L. | Sell | 24 662 | Common Stock |
| 2024-03-14 | Jeffs Roger | Buy | 16 976 | Common Stock |
| 2024-03-14 | Jeffs Roger | Buy | 13 000 | Common Stock |
| INSIDER POWER |
|---|
| 54.98 |
| Last 99 transactions |
| Buy: 2 269 939 | Sell: 680 650 |
Forecast:
15:07 - $68.78
Live Trading Signals (every 1 min)
Forecast
1: 13:37 - $68.44
Forecast 2: 14:27 - $68.77
Forecast 3: 15:07 - $68.78
SCORE
-10.00
Sell
-10.00
Sell
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $67.90 (3.32% ) |
| Volume | 0.883 mill |
| Avg. Vol. | 0.732 mill |
| % of Avg. Vol | 120.54 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For AXSM
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:33 | sell | $95.69 | N/A | Active |
|---|
AXSM
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
Latest Press Releases
2024-04-15 07:00:00 - Press Release
Axsome Therapeutics Highlights Innovative Neuroscience Portfolio At The American Academy Of Neurology (aan) 2024 Annual Meeting
Axs-05 in alzheimer's disease agitation data featured in oral plenary session new data for axs-07 in migraine demonstrating efficacy in pooled analysis presentations on cognitive and wake promoting effects of solriamfetol new york, april 15, 2024 (globe newswire) -- axsome therapeutics, inc. (nasdaq: axsm), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (cns) disorders, today announced presentations highlighting its innovative psychiatry and neurology pipeline at the american academy of neurology (aan) 2024 annual meeting, being held april 13-18, 2024, in denver, colorado. the presentations include an oral presentation during the clinical trials plenary session of data from the accord phase 3 trial of axs-05 in alzheimer's disease agitation (ada).
2024-04-10 07:00:00 - Press Release
Axsome Therapeutics To Report First Quarter 2024 Financial Results On May 6
New york, april 10, 2024 (globe newswire) -- axsome therapeutics, inc. (nasdaq: axsm), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (cns) disorders, today announced it will report its financial results for the first quarter of 2024 on monday, may 6, 2024, before the opening of the u.s. financial markets. axsome's management team will host a conference call at 8:00 a.m. eastern time on may 6, 2024, to discuss these results and provide a business update.
2024-04-01 07:00:00 - Press Release
Axsome Therapeutics Initiates Engage Phase 3 Trial Of Solriamfetol For The Treatment Of Binge Eating Disorder
New york, april 01, 2024 (globe newswire) -- axsome therapeutics, inc. (nasdaq: axsm), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (cns) disorders, announced the initiation of the engage phase 3 trial of solriamfetol, an investigational treatment for binge eating disorder (bed) in adults.
2024-03-25 07:00:00 - Press Release
Axsome Therapeutics Announces Results Of Crescendo Narcolepsy Patient Survey Demonstrating Unmet Needs In Treated Narcolepsy Type 1 Patients
77% of narcolepsy type 1 patients continue to experience cataplexy attacks despite being treated 64% of narcolepsy type 1 patients continue to experience excessive daytime sleepiness, as assessed by the epworth sleepiness scale (ess), despite being treated 74% of treated narcolepsy type 1 patients exhibit cognitive impairment, as assessed by the british columbia cognitive complaints inventory (bc-cci) depression and anxiety were experienced by 45% and 57% of narcolepsy type 1 patients, respectively new york, march 25, 2024 (globe newswire) -- axsome therapeutics, inc. (nasdaq: axsm), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (cns) disorders, today announced topline results from the crescendo (characterizing patient perspectives on unmet needs in narcolepsy) survey of patients with narcolepsy type 1 (nt1, i...
2024-03-25 06:30:00 - Press Release
Axsome Therapeutics Announces Axs-12 Achieves Primary Endpoint In The Symphony Phase 3 Trial In Narcolepsy
Axs-12 statistically significantly reduced cataplexy attacks compared to placebo (p=0.018, primary endpoint) axs-12 achieved statistically significant remission of cataplexy compared to placebo (p=0.008) axs-12 statistically significantly reduced excessive daytime sleepiness (eds) severity compared to placebo (p=0.027, cgi-s for eds) axs-12 statistically significantly improved concentration and memory compared to placebo (p=0.004, cognitive function items of fosq-10) axs-12 statistically significantly reduced overall severity of narcolepsy compared to placebo (p=0.007, cgi-s for narcolepsy) axs-12 statistically significantly improved overall function and quality of life compared to placebo (p=0...
Latest News
2024-04-02 11:26:09 - Zacks Investment Research
Axsome (AXSM) Begins Solriamfetol Binge Eating Phase III Study
Axsome's (AXSM) phase III ENGAGE study is set to evaluate the efficacy and safety of solriamfetol for the treatment of binge eating disorder in adults.
2024-03-27 07:44:00 - InvestorPlace
3 Strong Buy Biotech Stocks to Add to Your Q2 Must-Watch List
Biotech has seen its fair share of ups and downs, including a massive surge during the pandemic followed by a considerable dip. However, the industry will never go too far away from center stage as diseases and conditions will always need medicine and technology to treat them.
2024-03-26 12:26:04 - Zacks Investment Research
Axsome's (AXSM) Narcolepsy Drug Study Meets Primary Goal
Data from a late-stage study shows that a five-week treatment with Axsome's (AXSM) experimental narcolepsy drug reduced weekly cataplexy attacks by 83%, compared to 66% for placebo.
2024-03-25 06:55:30 - Reuters
Axsome Therapeutics sleep disorder therapy succeeds in late-stage trial
Axsome Therapeutics said on Monday its therapy for a sleep disorder met the main goal of a late-stage study.
2024-03-23 06:45:00 - The Motley Fool
Buying These Dirt-Cheap Stocks Could Be a Brilliant Move
Many investors appear to be underestimating Axsome Therapeutics. CRISPR Therapeutics has tremendous long-term prospects.
2024-03-21 12:36:29 - Zacks Investment Research
Why Is Axsome (AXSM) Down 4% Since Last Earnings Report?
2024-03-20 13:16:03 - Zacks Investment Research
Axsome (AXSM) Begins Dosing in Depression Study on Sunosi
Axsome (AXSM) doses the first patient in the phase III PARADIGM study evaluating Sunosi (solriamfetol) for treating major depressive disorder. The stock rises 6%.
2024-03-05 07:00:00 - GlobeNewsWire
Axsome Therapeutics to Present at the Leerink Partners Global Biopharma Conference
NEW YORK, March 05, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome's Chief Executive Officer, will participate in a fireside chat at the Leerink Partners Global Biopharma Conference on Wednesday, March 13, at 9:20 a.m. Eastern Time at the Fontainebleau in Miami Beach, Florida.
2024-02-27 07:00:00 - GlobeNewsWire
Axsome Therapeutics to Present at the TD Cowen 44th Annual Healthcare Conference
NEW YORK, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome's Chief Executive Officer, will participate in a fireside chat at the TD Cowen 44th Annual Healthcare Conference on Wednesday, March 6, from 9:50-10:20 a.m. Eastern Time at the Marriott Copley Place in Boston, Massachusetts.
2024-02-26 08:50:00 - The Motley Fool
3 Biotech Stocks to Buy and Hold for the Next 10 Years
CRISPR Therapeutics' recent major regulatory win could be the first of many. Axsome Therapeutics should ride the wave from its rich late-stage pipeline.